Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to…

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

- CTx-PDE6b demonstrated clinically meaningful…

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

• Leading medical oncologist and…

Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer

Arun is an award-winning engineer…

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization…

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Companies join forces bringing together…

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Collaboration to make use of…

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19.

ExeVir Bio and VIB-UGent’s bioRxiv…

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo to receive upfront and…

Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by Newton Biocapital, Wallonie Entreprendre and individual investors.

Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is…